AlphAIalphai — Financial news for AI agents
en.globes.co.ilSEP 22 min read$TEVA

Teva drug meets endpoints in celiac disease trial

Teva Pharmaceuticals reported positive Phase IIa trial results for its antibody TEV 408 in treating celiac disease, meeting primary endpoints and showing significant intestinal damage prevention. The company estimates potential sales of $1.5-2 billion if approved. TEV 408 also showed promise in treating vitiligo. Teva shares have risen 16% year-to-date, with a market cap of $42.2 billion.

Original reporting
en.globes.co.il
Published Sep 2, 2026, 3:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 5:24 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Teva drug meets endpoints in celiac disease trial — source image
Source · en.globes.co.il
Decision brief

The 30-second read

$TEVABullishHigh
01

Why it matters

The trial outcome could re‑price TEVA's pipeline valuation and influence investor sentiment toward biotech trial news.

02

Market read

Positive trial data for a large‑cap pharma may trigger short‑term buying and longer‑term valuation adjustments.

03

What to watch

Potential regulatory hurdles and the need for larger trials could delay commercialization.

Relevance 8/10Novelty 8/10Timing: announcement today

Background

Teva is a $42B NYSE‑listed pharma with a recent 16% YTD stock rise; the celiac disease market is sizable but currently limited to gluten‑free diets.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

Teva announced positive Phase IIa trial results for its anti‑IL‑15 antibody TEV‑408 in celiac disease, meeting primary endpoint.

Expected impact

upward pressure on TEVA stock in the near term

Evidence & confidence

First‑time disclosure of statistically significant efficacy and safety, a material catalyst for a large‑cap pharma.

Market effects

Sector

strengthens the celiac disease therapeutic pipeline and may spur competitor activity in IL‑15 targeting drugs

Regional

positive for US and Israeli biotech sectors

Global

adds to global interest in autoimmune disease treatments

Counterpoint

What could challenge this read

Phase IIa results may not translate to Phase III success; market may overprice the upside.

Key entities

  • Company
    Teva Pharmaceuticals

    US‑listed pharmaceutical company reporting the trial results.

  • Drug
    TEV‑408

    Anti‑IL‑15 antibody under investigation for celiac disease and vitiligo.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 4
$TEVAMed

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Teva Pharmaceuticals (TEVA) agreed to a stalking-horse bid of up to $125M for BioXcel Therapeutics' (BTAI) assets, including $57.5M in cash and up to $67.5M in contingent payments. The deal, subject to court approval, includes IGALMI and other assets. The FDA has a 2026 target date for a supplemental application to expand IGALMI's label to at-home use. Competing bids may arise.

finance.yahoo.com3 min
SEP 4
$TEVAMed

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

S&P Global Ratings upgraded Teva Pharmaceutical's long-term issuer credit rating to BBB- from BB+, reflecting strong financial performance and debt reduction. This is the third upgrade in recent months, with Teva now holding investment-grade ratings from all major agencies. The company's CFO attributed the upgrades to successful execution of its growth strategy and improved financial profile.

globenewswire.com1 min
SEP 2
$TEVAMedAI 8/10

Teva Stock Drops As Celiac Trial Fails To Impress - TipRanks.com

Teva Pharmaceutical's (TEVA) stock declined despite early-stage positive results from a Phase 2a trial of TEV-408 for celiac disease. Investors were unimpressed due to the lack of later-stage data or a commercialization timeline. The company is focusing on specialty medicines and biosimilars to stabilize growth but faces challenges from debt and generic revenue pressure.

tipranks.com2 min
SEP 2
$TEVAMedAI 8/10

Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial

Teva Pharmaceutical Industries' experimental drug TEV-53408 met its main goal in a mid-stage trial, preventing intestinal damage in celiac disease patients. The Phase 2a study showed significant improvement in intestinal health and symptom scores compared to placebo. Teva plans further studies and projects peak sales of $1.5B-$2B for the drug, which targets the IL-15 pathway. The company has a deal with Royalty Pharma for up to $500M in support.

medcitynews.com2 min
SEP 2
$TEVAMedAI 8/10

Teva Reports Positive Phase 2a Results For TEV-408 In Celiac Disease

Teva Pharmaceutical (TEVA) reported positive Phase 2a trial results for TEV-408, an anti-IL-15 monoclonal antibody, in celiac disease. The study met its primary endpoint, showing significant prevention of gluten-induced intestinal damage. TEV-408 also reduced inflammation and improved patient-reported outcomes. The company plans to present further data and host an investor call. TEVA stock closed at $36.19, up 0.39%, and is up 0.77% in pre-market trading.

rttnews.com2 min
SEP 2
$TEVAMedAI 8/10

Teva Pharma Reports Positive Topline Results From Ongoing Phase 2a Study Of TEV 408

Teva Pharmaceutical (TEVA) reported positive topline results from a Phase 2a study of TEV 408, an anti-interleukin-15 monoclonal antibody, for treating celiac disease. The study met its primary endpoint, showing significant prevention of gluten-induced intestinal damage compared to placebo. The company plans to present further data at a future scientific meeting. TEVA shares rose 2.96% in pre-market trading.

rttnews.com1 min